A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects With Advanced Malignancies

Trial Profile

A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects With Advanced Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs MSC 2363318A (Primary) ; Tamoxifen; Trastuzumab
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors EMD Serono
  • Most Recent Events

    • 28 Jun 2017 Planned number of patients changed from 130 to 129.
    • 28 Jun 2017 Planned End Date changed from 30 Apr 2018 to 3 Jan 2019.
    • 28 Jun 2017 Planned primary completion date changed from 30 Apr 2018 to 3 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top